ERBB2 and ovarian cancer: The discrimination of BOADICEA did not vary much by the clinical data of the proband other than showing some improvement for clinical conditions more strongly associated with PVs in BRCA1 than in the other genes, such as for ovarian cancer or ER and HER2 negative breast cancer (Supplementary Table S4).